Prevalence of hepatitis C in patients with primary antibody deficiency.
Concern over sporadic hepatitis C virus (HCV) infection from treatment with contaminated immunoglobulin in patients with immunodeficiency prompted use to screen serum from 44 patients for HCV RNA. We found no evidence of either horizontal or iatrogenic infection in our Clinic, except in two patients known to have received contaminated batches, and in one who had had regular plasma infusions. Thus, common variable immunodeficiency (CVID) patients in England do not have a high incidence of HCV infection despite exposure to various immunoglobulin products. This contrasts with the recently reported high prevalence in similar patients in Italy. Although our data reinforce the impression that both intramuscular and current licensed i.v. preparations in the UK are safe, manufacturers should be encouraged to PCR screen all batches of immunoglobulin for HCV.
Webster
A D
AD
Department of Clinical Immunology, Royal Free Hospital, London, UK.
Brown
D
D
Franz
A
A
Dusheiko
G
G
D000361:Agammaglobulinemia / Q000503:physiopathology / Q000628:therapy; D017074:Common Variable Immunodeficiency / Q000453:epidemiology* / Q000503:physiopathology / Q000628:therapy; D006526:Hepatitis C / Q000453:epidemiology* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects; D008111:Liver Function Tests; D015995:Prevalence
D016756:Immunoglobulins, Intravenous